Table of Contents

Articles

• You have access

  The rs35217482 (T755I) Single-Nucleotide Polymorphism in Aldehyde Oxidase-1 Attenuates Protein Dimer Formation and Reduces the Rates of Phthalazine Metabolism

  Hinata Ueda, Katsuya Narumi, Ayako Furugen, Yoshitaka Saito and Masaki Kobayashi

  Drug Metabolism and Disposition September 2022, 50 (9) 1126-1131; DOI: https://doi.org/10.1124/dmd.122.000902
• You have access

  Is the Protein-Mediated Uptake of Drugs by Organic Anion Transporting Polypeptides a Real Phenomenon or an Artifact?

  Mengyue Yin, Flavia Storelli and Jashvant D. Unadkat

  Drug Metabolism and Disposition September 2022, 50 (9) 1132-1141; DOI: https://doi.org/10.1124/dmd.122.000849
• You have access

  Antibiotics-Induced Disruption of Gut Microbiota Increases Systemic Exposure of Clopidogrel Active Metabolite in Type 2 Diabetic Rats

  Xue Chen, Yingrui Liu, Hongwei Yao, Wenfang Song, Yu Song, Jingkai Gu and Yingjie Guo

  Drug Metabolism and Disposition September 2022, 50 (9) 1142-1150; DOI: https://doi.org/10.1124/dmd.122.000906
• You have access

  The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro

  Yue Shen, William Eades, William Liu and Bingfang Yan

  Drug Metabolism and Disposition September 2022, 50 (9) 1151-1160; DOI: https://doi.org/10.1124/dmd.122.000918
• You have access

  Physiologically Based Pharmacokinetic Modeling of Vitamin D₃ and Metabolites in Vitamin D–Insufficient Patients

  Colton W. Sawyer, Stacey M. Tuey, Raymond E. West, Thomas D. Nolin and Melanie S. Joy

  Drug Metabolism and Disposition September 2022, 50 (9) 1161-1169; DOI: https://doi.org/10.1124/dmd.121.000609
• You have access

  Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib

  Louis Lin, Matthew R. Wright, Cornelis E.C.A. Hop and Harvey Wong

  Drug Metabolism and Disposition September 2022, 50 (9) 1170-1181; DOI: https://doi.org/10.1124/dmd.122.000885
• You have access

  High-Throughput Production of Diverse Xenobiotic Metabolites with Cytochrome P450–Transduced Huh7 Hepatoma Cell Lines

  Choon-myung Lee, Ken H. Liu, Grant Singer, Gary W. Miller, Shuzhao Li, Dean P. Jones and Edward T. Morgan

  Drug Metabolism and Disposition September 2022, 50 (9) 1182-1189; DOI: https://doi.org/10.1124/dmd.122.000900
• You have access

  Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

  Angela C. Doran, Woodrow Burchett, Connor Landers, Gabrielle M. Gualtieri, Amanda Balesano, Heather Eng, Alyssa L Dantonio, Theunis C. Goosen and R. Scott Obach

  Drug Metabolism and Disposition September 2022, 50 (9) 1259-1271; DOI: https://doi.org/10.1124/dmd.122.000884
• You have access

  An Improved Method for Cytochrome P450 Reaction Phenotyping Using a Sequential Qualitative-Then-Quantitative Approach

  Angela C. Doran, Alyssa L. Dantonio, Gabrielle M. Gualtieri, Amanda Balesano, Connor Landers, Woodrow Burchett, Theunis C. Goosen and R. Scott Obach

  Drug Metabolism and Disposition September 2022, 50 (9) 1272-1286; DOI: https://doi.org/10.1124/dmd.122.000883
• You have access

  Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin

  Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage and Timothy S. Tracy

  Drug Metabolism and Disposition September 2022, 50 (9) 1287-1301; DOI: https://doi.org/10.1124/dmd.122.000876
• You have access

  Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin

  Shen Cheng, Darcy R. Flora, Allan E. Rettie, Richard C. Brundage and Timothy S. Tracy

  Drug Metabolism and Disposition September 2022, 50 (9) 1302-1311; DOI: https://doi.org/10.1124/dmd.122.000877
• You have access

  Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease

  Yan Weng, Kari R. Fonseca, Yi-an Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, Andrew J. Bessire, Mathew A. Cerny, David A. Tess, A. David Rodrigues, Amit S. Kalgutkar, John Litchfield, Li Di and Manthena V. S. Varma

  Drug Metabolism and Disposition September 2022, 50 (9) 1312-1321; DOI: https://doi.org/10.1124/dmd.122.000953